Literature DB >> 7918934

Short report: interferon-alpha decreases 14C-aminopyrine breath test values in patients with chronic hepatitis C.

Y Horsmans1, R Brenard, A P Geubel.   

Abstract

OBJECTIVE: To investigate the effect of interferon-alpha on cytochrome P-450 dependent microsomal function.
METHODS: The 14C-aminopyrine breath test was performed before, during and after a standard dose of interferon-alpha (3,000,000 units three times per week) was administered for at least six months (nine patients with chronic hepatitis C).
RESULTS: Mean aminopyrine breath test values obtained during therapy were significantly lower than either pre- or post-treatment, the degree of reduction varying widely between individuals. Pre- and post-treatment aminopyrine breath test values did not differ significantly.
CONCLUSION: Interferon therapy is associated with a significant and transient inhibition of cytochrome P-450 activity, which should be taken into account when prescribing concurrent therapy with drugs metabolized by this pathway.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7918934     DOI: 10.1111/j.1365-2036.1994.tb00301.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

1.  Cytochrome P450 inactivation by serum from humans with a viral infection and serum from rabbits with a turpentine-induced inflammation: the role of cytokines.

Authors:  A M Bleau; M C Levitchi; H Maurice; P du Souich
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Parameters of microsomal and cytosolic liver function but not of liver perfusion predict portal vein velocity in noncirrhotic patients with chronic hepatitis C.

Authors:  C Herold; P Berg; D Kupfal; D Becker; D Schuppan; E G Hahn; H T Schneider
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

3.  Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy.

Authors:  Matthias Ocker; Marion Ganslmayer; Steffen Zopf; Susanne Gahr; Christopher Janson; Eckhart-G Hahn; Christoph Herold
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.